STOCK TITAN

Movano Inc - MOVE STOCK NEWS

Welcome to our dedicated news page for Movano (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Movano.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Movano's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Movano's position in the market.

Rhea-AI Summary
Movano Health (MOVE) completes successful hypoxia trial with UCSF, demonstrating accuracy of Evie Ring pulse oximeter surpassing FDA guidelines. Company expects FDA decision on 510(k) clearance in July 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.53%
Tags
none
-
Rhea-AI Summary
Movano Health (Nasdaq: MOVE) announced the shipping of its female-first wearable, the Evie Ring, marking a significant milestone for the company. The product was well-received at CES Unveiled and received several accolades from major press outlets. Movano Health plans to shorten order fulfilment times as it ramps up commercial production, with all orders placed before January 19, 2024 expected to ship out by February 20, 2024. The Evie Ring can be purchased exclusively at www.eviering.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Movano Health (MOVE) and ams OSRAM Collaborate to Include PPG Sensor Solution in Evie Ring, a CES Innovation Award Honoree
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.2%
Tags
none
Rhea-AI Summary
Movano Health (Nasdaq: MOVE) introduces the Evie Ring, the market's first women-focused smart ring, earning a 2024 CES Innovation Honoree Award. It redefines wearables with a unique design, female-specific data interpretation, and AI-based trend analysis. The ring begins shipping this month and comes with groundbreaking features such as smarter form factor, sensor, metrics, data analysis, and pricing. It is available at www.eviering.com in gold, rose gold, and silver finishes, catering to women's health and wellness needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
-
Rhea-AI Summary
Movano Health (Nasdaq: MOVE) announces that its wearable, the Evie Ring, is now eligible for HSA/FSA fund reimbursement, saving consumers 30-50% on qualifying direct to consumer health and wellness purchases. The company aims to make the Evie Ring accessible to more women, tapping into the estimated $150B HSA/FSA contributions annually. Movano Health also plans to showcase the Evie Ring at CES 2024, where it has been named a CES Innovation Award Honoree in Wearables.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
-
Rhea-AI Summary
Movano Health (Nasdaq: MOVE) to Showcase Blood Pressure Monitoring Technology at CES and JP Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
partnership
Rhea-AI Summary
Movano Health (Nasdaq: MOVE) announced that the Evie Ring, a smart ring designed for women's health, received a 2024 CES Innovation Honoree Award. The ring offers innovative features such as tracking menstrual cycles, sleep stages, and blood oxygen saturation, providing personalized insights to empower women with actionable health data. Movano Health also demonstrated breakthrough results in its blood pressure clinical trial and is making headway in non-invasive glucose monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
-
Rhea-AI Summary
Movano Health (Nasdaq: MOVE) announces successful ecommerce launch of the Evie Ring, driving over $1 million in orders through the Thanksgiving Holiday. The company is also spearheading innovation in blood pressure measurement technology, recently attaining accurate cuffless and continuous blood pressure monitoring. Additionally, Movano Health is making significant progress in non-invasive glucose monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
none
-
Rhea-AI Summary
Movano Health (Nasdaq: MOVE) introduces the Evie Ring, a smart ring designed for women, offering innovative design, women-focused metrics, and cross-data trend analysis. Orders start at 12 pm EST, providing a valuable tool for women's health and fitness tracking.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
Rhea-AI Summary
Movano Health (Nasdaq: MOVE) announced the closing of its $4.1 million underwritten public offering of 4,870,600 shares of its common stock, including the full exercise of the underwriter's over-allotment option. The public offering price was $0.85 per share. The net proceeds will be used for general corporate purposes, including funding product development and commercialization activities. The Benchmark Company, LLC acted as sole book-running manager for the offering, and K&L Gates LLP represented the Company in the transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
offering
Movano Inc

Nasdaq:MOVE

MOVE Rankings

MOVE Stock Data

22.89M
41.75M
9.7%
16.65%
0.07%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
United States
Pleasanton

About MOVE

movano is a health-focused technology company that believes glucose is an important health metric to continuously track, as glucose levels serve as a proxy for metabolic health and risk for chronic disease, such as diabetes. we also believe that whether you are a person with diabetes, prediabetes or someone looking to pursue a healthier lifestyle, monitoring and managing your glucose levels shouldn’t be painful, complicated or conspicuous.